The National Cancer Institute (NCI) awarded a $514,582 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of North Carolina at Chapel Hill (UNC-CH) to support research on "Targeting APOBEC3-Induced Squamous Differentiation in Bladder Cancer." The 5-year project aims to investigate the role of APOBEC3 enzymes in bladder cancer initiation, progression, and treatment resistance, with a focus on understanding how APOBEC3 promotes squamous differentiation. The research will leverage UNC-CH's expertise in bladder cancer biology, novel mouse models, and patient-derived tumor samples to provide insights into the mechanisms underlying APOBEC3-mediated tumor evolution and therapeutic resistance. The findings are expected to inform the development of new strategies to reverse APOBEC3-induced treatment resistance in bladder cancer.
Generated 3/18/25, 5:09 AM